RxDoctor Payments Data

Thomas Choi, MD

Ophthalmology · Downey, CANPI 1477555985

Payments from drug & device makers

$2,514in general payments, 2019–2025

Across 34 payments — averaging $73.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$1K
  • Beaver-visitec International, Inc.$301
  • Alcon$258
  • Kala Pharmaceuticals, Inc.$189
  • Bausch & Lomb Americas Inc.$112
  • AbbVie$65
  • plus $254 from 8 others

What the payments were for

  • Travel & lodging$1,12645%
  • Food & beverage$1,35154%
  • Gifts$371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,514 in reported general payments places this provider in the 60th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$268,484
Medicare patients
435
Services billed
2,704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine28$28,956
LumiganBimatoprost34$20,751
Prednisolone Acetate293$12,866
MoxifloxacinMoxifloxacin Hcl339$10,491
Azelastine Hcl184$6,119
Ketorolac Tromethamine221$6,032
Latanoprost366$5,696
Brimonidine Tartrate139$4,545
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat65$1,561
Timolol Maleate78$1,079
Dorzolamide Hcl31$510
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha48$477
ErythromycinErythromycin Base18$206
Ofloxacin12$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$65$49,70662 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Downey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →